

REMARKS

The Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed 10 Jun 2004 requires correction of sequences that are not accompanied by a sequence identifier. These errors have been corrected in the present substitute Sequence Listing, as well as other errors discovered in the Sequence Listing originally filed in the application on May 28, 2002.

The amendments to the specification with respect to identification of sequences and corrections of errors in the originally filed Sequence Listing are as follows:

Nucleotide sequences of ten or more nucleotides originally disclosed in the specification which were not identified with a sequence identifier have been assigned a sequence identifier at each occurrence in the specification and have been added to the substitute Sequence Listing. SEQ ID NOs:24, 25, 35 and 41 of the original Sequence Listing have been deleted from the Sequence Listing and re-used to identify previously unidentified sequences, as it was discovered that SEQ ID NOs:24, 25, 35 and 41 were duplicates of SEQ ID NOs:17, 18 and 33 (identical to both 35 and 41), respectively. The amendments with respect to new sequence identifiers are as follows:

REFERENCE	AMENDMENT
Page 7, line 2	SEQ ID NO:24 added
Page 7, line 7	SEQ ID NO:25 added
Page 12, line 30 Page 22, line 22 Page 27, line 4 Page 33, line 2 Claims 3, 5, 11, 13, 23, 25, 45 and 51,	SEQ ID NO:35 added
Page 12, line 31	SEQ ID NO:41 added
Page 12, line 32 Page 27, line 7	SEQ ID NO:44 added

Page 12, line 34 Page 27, line 6	SEQ ID NO:45 added
Page 12, line 35	SEQ ID NO:46 added
Page 13, line 1 Page 27, line 3	SEQ ID NO:47 added
Page 13, line 2 Page 27, line 1	SEQ ID NO:48 added
Page 13, line 4 Page 26, line 35 Page 26, line 35	SEQ ID NO:49 added
Page 22, line 23 Page 33, line 3	SEQ ID NO:50 added
Page 22, line 26 Page 33, line 4	SEQ ID NO:51 added
Page 22, line 27 Page 33, line 5	SEQ ID NO:52 added
Page 22, line 29 Page 33, line 6	SEQ ID NO:53 added
Page 22, line 30 Page 33, line 8	SEQ ID NO:54 added
Page 27, line 8	SEQ ID NO:55 added
Page 27, line 10	SEQ ID NO:56 added
Page 27, line 12	SEQ ID NO:57 added

In addition, certain nucleotide sequences of ten or more nucleotides which were assigned sequence identifiers in the originally filed Sequence Listing were not identified in the specification using the sequence identifier. These errors have been corrected as follows:

REFERENCE	AMENDMENT
Page 33, line 28	“SEQ ID NO:36” inserted
Page 40, line 27	“SEQ ID NO:33” inserted
Page 56, line 13	“SEQ ID NO:36” inserted
Page 56, line 16	“SEQ ID NO:37” inserted
Page 56, line 18	“SEQ ID NO:38” inserted
Page 56, line 21	“SEQ ID NO:39” inserted
Page 56, line 24	“SEQ ID NO:40” inserted
Table 2, page 59	SEQ ID NOs corresponding to BK1-PS, BK2-PS, BK3-PS, BK4-PS, BK5-PS, BK6-PS, BK7-DE and 1084 inserted


The following sequence identifier typographical errors have been corrected in the specification. Reference to the Sequence Listing shows that the sequences set forth do not correspond to the SEQ ID NOs shown (pages 13 and 27, and Table 2 SEQ ID NO:43), that multiple SEQ ID NOs are used to identify the same sequence (Table 1, SEQ ID NOs:33, 35 and 41), or that the sequence shown contains a typographical error when compared to the Sequence Listing (Table 2, SEQ ID NO:42):

REFERENCE	AMENDMENT
Page 13, line 18	“SEQ ID NO:15” replaced with “SEQ ID NO:16”; “SEQ ID NO:16” replaced with “SEQ ID NO:17”
Page 13, line 19	“SEQ ID NO:17” replaced with “SEQ ID NO:18”; SEQ ID NO:24 deleted in its entirety – duplicate of SEQ ID NO:17
Page 13, line 20	SEQ ID NO:25 deleted in its entirety – duplicate of SEQ ID NO:18
Page 27, line 14	“SEQ ID NO:17” replaced with “SEQ ID NO:33”
Table 1, page 58	“SEQ ID NO:35” “SEQ ID NO:41” replaced with “SEQ ID NO:33” – (35 and 41 are the same sequence as 33)
Table 2, page 59	“SEQ ID NO:43” replaced with “SEQ ID NO:33”
Table 2, page 59	In SEQ ID NO:42, 3’ “aca” replaced with “caa” to correspond with Sequence Listing

In view of the foregoing amendments, Applicant believes that the Sequence Listing and disclosure of sequences in the specification now comply with 37 CFR §1.821 through §1.825, and an action on the merits is respectfully requested. If the Examiner would like to discuss this matter or any aspect of the present application with Applicant, he is invited to call the

undersigned at the number shown below. Alternatively, the Examiner is invited to call
Applicant's representative at Kenyon & Kenyon.

Respectfully submitted,


Donna R. Fugit, Ph.D.
Reg. No. 32,135
Agent for Applicant

Genta, Inc.
Two Connell Drive
Berkeley Heights, NJ 07922
Tel. (908) 219-3195
Fax (908) 286-5982

Date: July 9, 2004